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Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents
(BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation
sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved
issue of drug-eluting stent (DES) implantation overall. The Absorb™ (Abbott Vascular, Abbott Park, IL, USA) is the
first CE approved DES with a bioresorbable vascular scaffold (BVS) thought to reduce long-term complication rates.
The EVERBIO II trial was set up to compare the BVS safety and efficacy with both EES and BES in all patients viable
for inclusion.
Methods/Design: The EVERBIO II trial is a single-center, assessor-blinded, randomized trial. The study population
consists of all patients aged ≥18 years old undergoing percutaneous coronary intervention. Exclusion criterion is
where the lesion cannot be treated with BVS (reference vessel diameter >4.0 mm). A total of 240 patients will be
enrolled and randomly assigned into 3 groups of 80 with either BVS, EES or BES implantation. All patients will
undergo a follow-up angiography study at 9 months. Clinical follow-up for up to 5 years will be conducted by
telephone. The primary endpoint is in-segment late lumen loss at 9 months measured by quantitative coronary
angiography. Secondary endpoints are patient-oriented major adverse cardiac event (MACE) (death, myocardial
infarction and target-vessel revascularization), device-oriented MACE (cardiac death, myocardial infarction and
target-lesion revascularization), stent thrombosis according to ARC and binary restenosis at follow-up 12 months
angiography.
Discussion: EVERBIO II is an independent, randomized study, aiming to compare the clinical efficacy, angiographic
outcomes and safety of BVS, EES and BES in all comer patients.
Trial registration: The trial listed in clinicaltrials.gov as NCT01711931.
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Drug-eluting stents (DES) have considerably reduced
neointimal hyperplasia and significantly decreased the
risk of restenosis compared to bare metal stents (BMS)
[1]. However, the persistent polymer within the vessel
lumen has been held responsible for ongoing endothelial
inflammation, incomplete endothelialization and subse-
quent atherosclerosis, all leading to late complications
such as restenosis and stent thrombosis [2].
Everolimus-eluting stents (EES) and biolimus-eluting
stents (BES) are more recent DES that have been widely
investigated. The EES is at present the most frequently
used DES in the USA and in Europe [3]. It was demon-
strated as non-inferior to sirolimus-eluting stents (SES)
in the ISAR-TEST IV and the EXCELLENT trial and
superior to paclitaxel eluting stents (PES) in two large
randomized studies (Spirit-IV and COMPARE) [4-7].
One propensity score matched registry (LESSON-1)
showed a trend towards a lower risk of death, myocar-
dial infarction (MI) and target-vessel revascularization
(TVR) as compared to SES over a 3-year follow-up [8].
BES differs from EES in that it possesses an abluminal
polymer coating that is completely converted to lactic
acid in 6 months and, via the Krebs cycle, to carbon
dioxide and water in 6 to 9 months. Two large clinical tri-
als (NOBORI and LEADERS) proved its non-inferiority to
PES and SES at 9 months and 4 years, respectively [9,10].
The propensity score matched EVERBIO trial showed
similar risk of death, MI and TVR in BES compared to
EES during a 2-year follow-up [11]. Recently, the random-
ized COMPARE II trial enrolling 2,707 patients, confirmed
the BES safety but no differences were observed in clinical
endpoints at 2-year follow-up when compared to EES
[12]. The ongoing Global LEADERS trial with an expected
inclusion of >10,000 patients will provide further informa-
tion on BES. The lactic acidification of the media from the
polymer could impact vascular healing at the stent vicinity
and promote a deleterious inflammatory reaction [13].
The unresolved problem of neointimal proliferation
and very late stent thrombosis from lingering polymers
and vascular scaffolds, led to the development of new-
generation completely resorbable stents. The Absorb™
(Abbott Vascular, Abbott Park, IL, USA) is the first CE
approved DES with a bioresorbable vascular scaffold
(BVS). It uses a poly-L-lactide polymer that is absorbed
after approximately 2 years via the Krebs cycle. A pro-
spective, open-label, 2-stage study called ABSORB in-
cluding 131 patients was conducted in Europe and
New Zealand and led to its approval by the EU in January
2011 for the treatment of coronary artery lesions [14]. The
major adverse cardiac event (MACE) rate was reported as
6.8% at 2-years follow-up and late lumen loss (LLL)
0.27 mm at 12 months [15,16]. Its non-inferiority to the
Xience Prime (Abbott Vascular), an EES, is currentlyunder investigation in the international ABSORB EX-
TEND trial that plans to enroll 1,000 patients
(NCT01023789). To date, there is no data on BVS com-
pared to EES or BES, and independent trials are eagerly
awaited. We seek to compare the efficacy and safety pro-
files of these three different types and generations of DES.Study objectives and hypothesis
The purpose of the EVERBIO II trial is to evaluate the
efficacy, angiographic outcome and safety of three differ-
ent stents in de novo coronary artery lesions: the BVS
Absorb™ (Abbott Vascular), the EES Promus Element™
(Boston Scientific, Natick, MA, USA) and the BES Bio-
matrix Flex™ (Biosensors International Ltd., Morges,
Switzerland). The null hypothesis to be rejected is that
all three stents are of equal efficacy. We believe there
will be a significant difference with regard to LLL at 9
months and a clinical endpoint of death, MI and TVR
at 12 months between EES and BES and BVS stents.Methods/Design
Study design and overview
This is a single center, assessor-blinded, randomized
study comparing three different stents in de novo coron-
ary lesions: the Absorb™, the Promus Element™ and the
Biomatrix Flex™. The protocol of the trial has been regis-
tered online (NCT01711931) at http://www.clinicaltrials.
gov. Figure 1 briefly summarizes the main study steps
and Table 1 the longitudinal follow-up. The organization
and scientific conduct is supervised by a Steering Com-
mittee. A Data and Safety Monitoring Board is respon-
sible for safety and ethical aspects. A Clinical Events
Adjudication Committee (CEAC) including interven-
tional and non-interventional cardiologists review and
adjudicate all reported events and endpoints and per-
form computation and angiographic measurements. All
members of the CEAC are blinded to the primary results
of the trial. The study complies with the Declaration of
Helsinki and was approved by the local ethics committee
of Fribourg University and Hospital (Switzerland, 043/
12-CER-FR).Study endpoints
The primary endpoint is LLL at 9 months as assessed by
quantitative coronary angiography. The secondary end-
points are divided in angiographic and clinical findings.
We will assess angiographic success, device success and
binary restenosis at 9 months. Clinical endpoints include
a patient-oriented MACE (composite of death, MI and
TVR) a device-oriented MACE (composite of cardiac
death, MI and target lesion revascularization (TLR)) and
stent thrombosis (ST) at 6 months, and 1, 2 and 5 years.
Figure 1 Study algorithm. BES: biolimus-eluting stent, BVS: biovascular scaffold, EES: everolimus-eluting stent, OCT: optical coherence
tomography, PCI: percutaneous coronary intervention. aPrimary endpoint: late lumen loss at 9-month angiography study. bSecondary endpoints:
patient oriented (death, myocardial infarction, target vessel revascularization), device oriented (cardiac death, myocardial infarction, target-lesion
revascularization), stent thrombosis, binary restenosis at 9-month angiography study.
Table 1 Timetable of prospective investigations
Investigation Baseline Post procedure 3 months 6 months 9 months 12 months 2 years 5 years
Medical/clinical history x x x x x x x x
Physical examination x x x
12-lead ECGa x x x
Coronary angiogramb x x
Procedural complications x x
Laboratory surveyc x x
CK, CK-MB, troponind x x
Medications x x x x x x x x
Primary outcome x
Secondary outcome x x x x x x
aAny ECG may be obtained when clinically relevant.
bUnscheduled angiograms after 6 months will be considered 9-month follow-up angiograms.
cUsual laboratory survey include, complete blood count, electrolytes, fasting glucose level, INR, prothrombin time, partial thromboplastin time, creatinine, blood
urea nitrogen, pregnancy test if applicable.
dAll patients will benefit from cardiac enzyme measurement 4 h post procedure, enzymes may be followed every 8 h if clinically relevant and at the discretion of
the operator.
CK creatine kinase, ECG electrocardiogram.
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All patients aged ≥18 years undergoing coronary angiog-
raphy at the University & Hospital Fribourg (Switzerland)
for suspected coronary artery disease on functional cardiac
testing, stable angina or acute coronary syndrome
(unstable angina, non-ST segment MI, ST-elevated MI)
are eligible. Patients must be apt and willing to provide
written informed consent and participate in follow-up. Pa-
tients with a known or presumed hypersensitivity to hep-
arin, antiplatelet drugs and hypersensitivity to contrast dye
not controllable with standard premedication will be ex-
cluded. Patients are recruited on the day of their angiog-
raphy by one of the investigators if all inclusion criteria
are met and no exclusion criteria apply. Written informed
consent will be obtained as required by the local institu-
tional ethics committee in accordance with the Declar-
ation of Helsinki.
Treatment assignment
Patient randomization will be performed after lesion prep-
aration. Exclusion criterion is when the lesion cannot be
treated with BVS (reference vessel diameter >4.0 mm).
Randomization will be completed via computer-generated
numbers. Allocation concealment will be kept in sealed en-
velopes containing a non-transparent pleated color sheet
in which the etiquette for intervention is embedded. The
investigator is responsible for enrolment and a study nurse
will assign participants to either stent implantation. Only
the outcome assessors and data analysts are blinded to the
intervention.
Index percutaneous coronary intervention
Procedures will be performed via the femoral or radial
artery with a 5-6 French (F) guiding catheter. Standard
interventional techniques will be used and performed
according to practice guidelines. Preprocedural anti-
thrombotic regimen is systematically achieved with as-
pirin (500 mg intravenous bolus for those not under
treatment and 100 mg for those already under aspirin
and then 100 mg/day for all) and unfractionated heparin
(70 UI/kg), whereas glycoprotein IIb/IIIa inhibitors are
used per operator discretion. All patients will receive
either a minimum 600 mg loading dose of clopidogrel,
180 mg of ticagrelor, or 60 mg prasugrel before or im-
mediately after the procedure. Lifelong ≥100 mg daily
aspirin and either 75 mg daily clopidogrel, or 90 mg
twice-daily ticagrelor or 10 mg prasugrel for a minimum
of 6 months will be prescribed. Other medications will
be prescribed as per standard of care. All patients will
be monitored between 4 to 12 h in an intermediate care
unit and will undergo baseline and 3 to 6 h cardiac
biomarker measurements. A standard 12-lead electro-
cardiogram (ECG) is recorded immediately after the
procedure and with each biomarker measurement.Follow-up coronary angiography
Effectiveness will be measured at the 9-month follow-up
angiography in all patients. Quantitative measures will
be performed within the stent and the 5 mm edge re-
gion. In-segment LLL will be defined as the difference
between the minimum lumen diameter post procedure
and at 9 months. Binary restenosis will be defined as
>50% diameter stenosis. LLL is computed through quan-
titative coronary angiography with the use of automated
edge-detection system (CAAS II, Pie Medical Imaging,
Maastricht, The Netherlands). Any unscheduled angio-
gram after 6 months will be considered as 9-month
follow-up angiogram.
Optical coherence tomography (OCT) is conducted in
the first 30 patients of each group willing to undergo the
aforementioned procedure. Percentage of malapposed
struts, frequency of abnormal intrastent tissue, frequency
of peristrut low intensity area and percent net volume
obstruction will be assessed with the use of automated
edge-detection system (Illumien-optis ORW, St. Jude
Medical, St. Paul, MN, USA).
Clinical follow-up
Patients will be followed clinically by clinic visits or by
telephone interview at 3, 6, 9 and 12 months, and 2 and
5 years. No blinding will be present during the collection
of outcome data. If the patient is not accessible, data can
be retrieved from the referring physician or the hospital
electronic database.
Statistical analyses
We plan to enroll 80 patients in each group. Compari-
son between EES and BES with BVS will necessitate a
total of 240 patients in order to achieve a power of 90%
to prove a difference of 0.2 mm LLL at 9 months (BES
and EES = 0.3 mm vs BVS 0.5 mm; SD 0.5 mm). This al-
lows for a dropout rate of 20% of the sample in which
case the study would still yield a power of 83%. Sample
size calculations were performed using Sample Power 3
(SPSS Inc, Chicago, IL, USA) at a two-tailed significance
level of α = 0.05.
Continuous variables are presented as mean ± standard
deviation or median (25% to 75%) interquartile range ac-
cording to their distribution. Categorical variables are
presented as counts and percentages. Comparison be-
tween the individual groups and comparison between
BES and EES and BVS are performed on demographical
data and risk factors as well as on procedural characteris-
tics. The primary outcome is analyzed using a parametric
or nonparametric test according to distribution and by the
computation of a multivariate linear analysis by taking into
account significant risk factors that potentially influence
outcome thus adjusting for them. Clinical endpoints are
compared using the Kaplan-Meier method. Binary logistic
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pendent predictors for the secondary endpoints. All
analyses are performed according to the intention-to-
treat principle. An intermediate analysis will be per-
formed after follow-up angiography of 40 patients in
each group.
Trial interruption
The trial will be halted should the incidence of clinical
endpoints significantly differ between the different de-
vices during the intermediate analysis. The trial will also
be halted should the incidence of adverse clinical events
exceed the expected values at any point. The incidence
of clinical events is under constant observation of the
DSMB and CAEC. The principal investigator is continu-
ously informed by the DSMB and CAEC and is, by not
being blinded, solely responsible for trial halting.
Discussion
Although DES have revolutionized percutaneous coronary
interventions by significantly reducing clinically relevant
restenosis and ‘target-lesion’ revascularization [17-20], nu-
merous reports have since demonstrated an increased in-
cidence of late stent thrombosis (LST) [21-23]. This is
primarily due to a hypersensitivity reaction with secondary
delayed arterial healing [24,25]. Substantial efforts have
been made during the last decade to develop bioresorbable
materials such as transient polymers or temporary ‘scaf-
folds’. The rationale for creating such devices was to lower
both the neointimal proliferation in the short term and
the hypersensitivity reaction (leading to late stent throm-
bosis) in the long term. Ideally, the device would offer an
acute transient radial strength and later be completely
absorbed thereby restoring vascular physiology.
Several DES using bioresorbable materials are cur-
rently available. The most used and studied so far is the
Biomatrix™ BES. BES is a metallic stent that uses an
abluminal bioresorbable polymer coating. This polymer
is completely converted to lactic acid by 6 months and,
via the Krebs cycle, to carbon dioxide and water by 6 to
9 months. More recently, a fully bioresorbable coronary
scaffold has been launched for clinical use. The Absorb™
BVS is the first, fully bioresorbable coronary scaffold to
have been launched for clinical use with CE approval. It
uses a poly-L-lactide polymer that undergoes a four-
stage bioresorption through hydration, depolymerization,
polymer fragmentation and dissolution over 2 years via
the Krebs cycle [26]. BVS was chiefly used in simple pa-
tients and lesions during early phases trials (ABSORB co-
hort A and B; ABSORB EXTEND). A second-generation
device was developed to overcome the initial limitations of
early scaffold shrinkage and provide greater radial support.
Putative advantages over conventional DES are early res-
toration of physiological processes, namely vasomotionand remodeling, superior conformability, beneficial edge-
vascular response and suppression of late-stent malapposi-
tion [27]. BVS absorption and vascular remodeling seem
to seal stable plaques in settings of stable angina and type
A lesions. With its widespread clinical launch in 2012, lit-
tle is known on the broader use in more complex cases or
acute coronary syndromes. The use of the BVS in complex
situations makes sense however, as the risk of long-term
complications from conventional DES implantation is
even higher (longer lesions, chronic total occlusion, acute
coronary syndromes and so on). For the time being, evi-
dence has only provided information on its non-inferiority
to modern DES in very specific settings. The EVERBIO II
trial will assess BVS efficacy compared to the latest DES
on the market in all patients viable for inclusion experien-
cing more complex lesions and clinical situations.
Trial status
The recruitment phase is complete as of November 2013.
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